The analysis of some CFTR gene mutations in a small group of cf patients from southern part of Romania by Lucian GAVRILA et al.
The analysis of some CFTR gene mutations in a small group of CF patients from Southern part of Romania 
  8 
 
THE ANALYSIS OF SOME CFTR GENE MUTATIONS IN A SMALL GROUP 
OF CF PATIENTS FROM SOUTHERN PART OF ROMANIA 
 
Pompilia
 APOSTOL
*, Dănuţ CIMPONERIU
*, Irina RADU
*, Lucian GAVRILĂ
* 
 
*Human Genetics and Molecular Diagnostic Laboratory, Institute of Genetics, University of Bucharest, Romania 
Corresponding author: Pompilia Apostol, Human Genetics and Molecular Diagnostic Laboratory, Institute of Genetics, University of Bucharest, 
1-3 Intrarea Portocalelor Str., District 5, 060101 Bucharest, Romania, tel.: 0040213181576, fax: 0040213181565, e-mail: 
apostol_pompilia@yahoo.com 
 
Abstract.  Cystic  fibrosis  is  the  most  common  hereditary  disease  in  European  descendant  populations,  with  prevalence 
depending on ethnic groups studied. In contrast to other European countries, there is little information regarding the frequency of 
CFTR mutations for the Southern part of Romania. The aim of this study was to test the presence of nine CFTR mutations in CF 
patients from the Southern part of Romania, using complementary analysis methods. We investigated a group of unrelated CF 
patients (n=19) and, when possible, their voluntary parents (n=15). We observed that the most frequently worldwide CF mutation, 
∆F508, was present in 17 of our patients (89.5%) in homozygous (n=7) or heterozygous (n=10) condition and absent in 2 cases 
(10.5%). This mutation was also detected in ten parents, seven of them (100%) have homozygous children and three (37.5%) 
have heterozygous children for ∆F508 mutation. None of the G542X, S549N, G551D, R553X, R560T, S1255X, W1282X and 
N1303K mutations have been detected in the samples from patients or parents. Our results are partially similar with those reported 
in neighbouring countries where the ∆F508 is the most common mutation detected and the frequency of R560T, S549N, G551D and 
S1255X mutations is near zero. The enlargement of this study could give a better result regarding the spectrum of CFTR mutations 
in Romanian patients with CF. 
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INTRODUCTION  
 
Cystic  fibrosis  (CF)  is  an  autosomal  recessive 
disorder,  caused  by  mutations  in  the  cystic  fibrosis 
transmembrane conductance regulator gene (CFTR) on 
chromosome 7q31. The normal CFTR gene product is a 
chloride  channel  found  in  the  apical  membrane  of 
epithelial cells, able to regulates other ion channels [1, 
11, 22, 23]. A defective CFTR protein determines an 
abnormal  chloride  transport,  elevated  sweat  chloride 
and  the  production  of  thick  and  sticky  mucus.  This 
mucus clogs in the lung, intestines, exocrine pancreas 
and  reproductive  systems.  Recurrent  and  persistent 
pulmonary infections lead to respiratory failure which 
is the main cause of morbidity and mortality. Although 
elevated  sweat  chloride  values  sustain  a  clinical 
diagnosis  of  CF,  the  testing  for  disease-causing 
mutations  is  helpful  for  establish  the  definitive 
diagnostic. 
More  than  1600  sequence  variants  have  been 
reported since the cloning of the CFTR gene [4, 13, 
21]. Few of them are worldwide present, several are 
distributed  only  in  an  ethnic  group,  while  the  great 
majority  are  very  rare,  being  considered  regional  or 
“private”.  The  mutation  ∆F508,  consisting  in  the 
deletion  of  three  nuclotides,  is  present  at  majority 
(~70%) of patients with CF [13]. The high prevalence 
of the CF in certain populations could be explained by 
recurrent  mutations,  the  founder  effect  or  by  the 
heterozygote advantage [20]. The CF has the highest 
incidence in Caucasians and Ashkenazi Jews (1:2500 
and 1:2270, respectively), while the lower are in Asian 
and African populations [10, 18]. The CFTR mutations 
in  Romania  was  investigated  especially  for  patients 
from the Western part of country [8, 19].  
The aim of this study was to test the presence of 
nine CFTR mutations in CF patients from the Southern 
part  of  Romania  using  complementary  analysis 
methods.
 
MATERIALS AND METHODS 
 
Unrelated  CF  patients  (n=19)  and  their  parents 
(n=15) who lived in the Southern part of Romania were 
selected  from  Bucharest  pediatric  hospitals.  The  CF 
diagnosis  was  based  on  clinical  data  and  was 
confirmed  by  the  sweat  test  (cutoff,  60  mEq/L). 
Informed  oral  consent  was  obtained  from  patient’s 
parents before selection for this study. 
Genomic  DNA  was  extracted  from  all  EDTA-
treated  blood  samples  using  a  classical  protocol  and 
then  was  stored  at  -20
oC.  We  tested  nine  mutations 
located in CFTR exons 10, 11, 20 and 21 (Table 1) [12, 
16]. The specific restriction endonucleases (5 Units per 
reaction) were used to digest the amplicons for three 
hrs in conditions recommended by  manufacturers. In 
order to give an accurate and rapid molecular diagnosis 
for the  most common CF  mutation,  ∆F508,  we used 
two alternative analysis methods: PCR-mediated site-
directed  mutagenesis  [9]  and  high  resolution  melting 
analysis (HRM). After amplification, the first method 
requires PAGE (20%, TBE 1x, 5V/cm) of restriction 
products and silver staining, while the second requires 
the denaturation of amplicons. The PCR mixture (25 
µl)  contained  1.2  µl  of  genomic  DNA,  12.5  µl  of 
SensiMix HRM, 1 µl of EvaGreen (Quantace), 250 nM 
of each primer and double distillated water. We used 
the same primers as for the PCR-RFLP method. The 
temperature  cycling  conditions  were:  10  minutes  at 
95°C followed by 45 cycles of 95°C for 15 seconds, 
54°C  for  25  seconds,  72°C  for  10  seconds.  This 
protocol  continues  with  one  cycle  of  120  seconds  at 
95°C and 20 seconds at 72°C and is followed by a melt 
step  of  72–90°C  (0.1°C  increment,  pausing  for  2 
seconds  per  step)  in  a  Rotor-Gene  6000  with  HRM 
(Corbett Research). 
The study was in accordance with the Declaration 
of Helsinki. 
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Table 1. Summary presentations of methods used in this study for mutations detection  
 
Nr. 
crt.  Mutation  Type of 
mutation  Exon  Frequency 
worldwide  Method (restriction endonuclease)  Size of normal 
fragment 
Size of mutant 
fragment 
1.  ∆F508  Deletion  exon 10  66.8% [7]  PCR-mediated site-directed mutagenesis (MnlI)  56+30 bp  83 bp 
2.  G542X  Substitution  exon 11  2.6% [10]  PCR-mediated site-directed mutagenesis (MvaI)  171+100 bp  271 bp 
3.  S549N  Substitution  exon 11  0.1% [2,17]  PCR-RFLP (DdeI)  13, 238+174 bp  13+412 bp 
4.  G551D  Substitution  exon 11  1.5% [10]  PCR-RFLP (MboI)  425 bp  182+243 bp 
5.  R553X  Substitution  exon 11  0.7% [10]  PCR-RFLP (Hinc II)  239+186 bp  425 bp 
6.  R560T  Substitution  exon 11  0.2 % [21]  PCR-RFLP (TaiI)  425 bp  215+210 bp 
7.  S1255X  Substitution  exon 20  0.2% [21]  PCR-RFLP (HindIII)  473 bp  261+212bp 
8.  W1282X  Substitution  exon 20  1% [10]  PCR-RFLP (MnlI)  288 +185 bp  473 bp 
9.  N1303K  Substitution  exon 21  1.6 [10]  PCR-mediated site-directed mutagenesis (MvaI)  266+24 bp  290 bp 
 
RESULTS  
 
The  biological  samples  were  screened  for  the 
presence of the nine CFTR mutations by PCR-RFLP 
methods.  For  the  homozygous  ∆F508  affected 
individuals, a  single 83-bp  fragment is revealed, and 
for the normal condition, two fragments of 56- and 30-
bp  are  present.  The  ∆F508  in  heterozygotes  state  is 
considered when 83-bp, 56- and 30-bp were identified. 
An additional band, representing the heteroduplex, may 
be  also  encountered.  It  represents  an  indicator  of 
heterozygosity, but not a proof for a specific mutation 
(Fig. 1) [9]. The ∆F508 mutation was absent in 2 (10,5) 
patients and was identified in 17 patients (89.5%) in 
homozygous (n=7) or heterozygous (n=10) condition. 
This mutation was also detected in ten parents, seven 
of them (100%) have homozygous children and three 
(37.5%)  have  heterozygous  children  for  the  ∆F508 
mutation. No other mutation has been detected in the 
patients or in the parents groups (Table 2). 
We  obtained  by  HRM  analysis  three  patterns 
corresponding  to  the  three  conditions:  homozygote 
normal, heterozygote ∆F508/N and homozygote ∆F508 
(Fig. 2). This analysis confirms the results provided by 
the PCR-RFLP method. 
 
Table 2. Type of CFTR mutations detected in the analyzed samples 
 
Patient’s genotype  Parent’s genetic status  Nr. 
Crt. 
Mutation 
Homozygous  Heterozygous  Carrier  Non-carrier 
1.  ∆F508  7  10  10  5 
2.  G542X  0  0  0  0 
3.  S549N  0  0  0  0 
4.  G551D  0  0  0  0 
5.  R553X  0  0  0  0 
6.  R560T  0  0  0  0 
7.  S1255X  0  0  0  0 
8.  W1282X  0  0  0  0 
9.  N1303K  0  0  0  0 
 
 
 
Figure 1. The result of a test for the ∆F508 mutation (PAGE 20%, silver staining). Lines 1, 3, 4, 5, 9 – genotype 
∆F508/ ∆F508; Lines 2, 6 – genotype ∆F508/n; Lines 7 , 8 – normal genotype , MG – 100 bp DNA 
ladder (Fermentas) 
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DISCUSSIONS 
 
In the majority of cases, the clinical diagnosis of CF 
is confirmed by elevated (>60 nmol/l) sweat chloride 
concentrations  and,  when  possible,  by  screening  the 
CFTR gene for mutations. However, because this gene 
has  a  high  number  of  very  rare  mutations,  the 
possibility  to  test  all  CFTR  mutations  for  each  CF 
patients is practically impossible. In the last time, the 
detection rate of mutations was improved in different 
research  centers  by  different  methods:  heteroduplex 
analysis  (HA),  single-strand  conformation 
polymorphism  analysis  (SSCP),  denaturing  gradient 
gel electrophoresis (DGGE) methods, two-dimensional 
gene  scanning  technique  (TDGS)  and  HRM  (High 
resolution melting) analysis [3, 14, 15], allele specific 
oligonucleotide  (ASO),  amplification  refractory 
mutation  system  (ARMS),  oligo-ligation  assay. 
Different commercial kits also provided solutions for 
detection of the most common mutations. However, a 
panel  of  25  of  the  most  frequently  mutations  were 
recommended to be tested for CF molecular diagnosis. 
For the compound heterozygous patients, carrying one 
common and one very rare mutation, additional tests 
are required [5, 6].  
In  order  to  test  the  presence  of  some  CFTR 
mutations, we tested blood samples from patients with 
CF  (n=19)  and  15  of  their  parents  living  in  the 
Southern part of Romania. In this study we investigated 
the  most  frequently  five  mutations,  represented  by 
∆F508, G542X, N1303K, G551D and W1282X. All of 
these mutations have a worldwide estimated frequency 
higher than 1% (Table 1). We have also analyzed other 
four mutations, S549N, R553X, R560T and S1255X, 
which have a frequency lower than 1%, but are located 
nearby some  mutations analyzed in this study. Some 
studies  which  have  analyzed  the  genotype-phenotype 
correlation, have been shown that the nine mutations 
investigated in our study are associated with a severe 
CF  phenotype,  being  included  in  the  25  mutations 
panel  recommended  to  be  used  for  a  population 
screening [25]. We also try to determine the feasibility 
of HRM analysis for the detection of CFTR mutations. 
In  literature,  HRM  is  estimated  to  be  able  to 
discriminate  samples  which  present  small  mutations, 
like substitutions [24, 26]. By our experience, although 
HRM  represent  a  fast  method  for  detection  of  the 
common ∆F508 mutation, the results are difficult to be 
replicated. A possible explanation is represented by the 
protocol used for DNA extraction or by other technical 
problems.  
The  ∆F508  mutation,  in  homo-  (n=7)  or 
heterozygous  (n=10)  state,  was  observed  in  the 
majority of our patients (89.5%). 
The absence of the eight mutations tested could be 
explained by the lot size and, partly, by the background 
of  geographic  area.  Thus,  the  S549N,  R560T  and 
S1255X  mutations  were  reported  to  have  a  null 
frequency in the majority of neighboring countries. It 
has been showed that in samples from Russia, Estonia, 
Lithuania,  Ukraine,  Hungary,  Bulgaria,  Turkey, 
Croatia, Macedonia and Greece the  mutation  G551D 
was  identified  with  a  frequency  of  1,1%  only  in 
Croatia,  while  the  mutations  S549N,  R560T  and 
S1255X  were  not  present  [2].  The  data  obtained  for 
Romanian CF patients were also presented in another 
two studies: one for the Western part of country and 
the other for patients enrolled from different medical 
centers  [8,  19].  The  highest  mutation  frequency  was 
attributed to ∆F508 in both of these studies, as well as 
in  our  investigation.  The  G551D,  S549N,  R553X, 
R560T, S1255X mutations assessed but not detected in 
the present investigation have not been included in any 
of the two already mentioned studies.  
Because  the  remaining  mutations  were  not 
identified  in  a  previous  study  on  the  Romanian 
population, it is possible that their frequency to be as 
smaller  as  those  reported  for  general  European 
population.  
The molecular analysis used in this study could be 
applied for testing other mutations in CFTR gene. The 
investigation of the whole CFTR gene in patients from 
the entire Romania will improve our knowledge about 
the type and the frequency of the CFTR mutations.  
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